...
首页> 外文期刊>European review for medical and pharmacological sciences. >One stage percutaneous transhepatic biliary stenting for malignant jaundice: a safe, quick and economical option of treatment
【24h】

One stage percutaneous transhepatic biliary stenting for malignant jaundice: a safe, quick and economical option of treatment

机译:恶性黄疸的一级经皮经皮胆道支架:一种安全,快速,经济的待遇选择

获取原文
   

获取外文期刊封面封底 >>

       

摘要

OBJECTIVE: Patients with proximal malignant jaundices are often diagnosed in an advanced stage and need biliary decompression treatments, such as percutaneous transhepatic biliary drainage (PTBD) and bare metal stenting (BMS), to improve the hepatic function. Whether it is better to perform those two procedures together or in a separate time, it is not well understood. The aim of this study was to investigate the effectiveness and cost-benefit of a combined “one-stage” PTBD/BMS procedure in patients with malignant jaundices. PATIENTS AND METHODS: Forty-five patients with malignant jaundice treated with “one-stage” PTBD/BMS were retrospectively enrolled to evaluate technical success, complications, survival, and length of hospitalization. RESULTS: A full technical success of the procedures was reported for all patients, with only one major complication among 45 treated patients. A better performance in terms of hospitalization rate was achieved by the one-stage procedure compared to the two-stage, also resulting in global saving of costs. A high survival rate was observed at the 3rd and 6th month (97.7% and 86.6%, respectively), with a median overall survival time of 271,58 days. CONCLUSIONS: Our study shows that performing PTBD/BMS as a “one-stage” procedure is useful, safe, and cost-effective with a high percentage of technical success and a similar occurrence of complications compared to the two-stage procedure.
机译:目的:近端恶性黄疸的患者通常被诊断为晚期阶段,需要胆汁减压处理,例如经皮肾上腺胆道引流(PTBD)和裸金属支架(BMS),以改善肝功能。是否更好地在一起或在单独的时间内执行这两个程序,并不是很好地理解。本研究的目的是调查恶性黄疸患者组合“单阶段”PTBD / BMS程序的有效性和成本效益。患者和方法:回顾性地注册了患有“单级”PTBD / BMS的45例恶性黄疸患者,以评估技术成功,并发症,存活和住院时间。结果:所有患者报告了该程序的全面技术成功,只有45例治疗患者中的一个主要并发症。与两阶段相比,一阶段过程实现了在住院率方面的更好表现,也导致全球节省成本。在第3个月和第6个月(分别为97.7%和86.6%)观察到高存活率,中位数总生存时间为271,58天。结论:我们的研究表明,以“单级”程序表演PTBD / BMS是有用,安全,并且具有成本效益,与两阶段程序相比,高百分比的技术成功和类似的并发症发生。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号